1
|
Ewbank F, Gaastra B, Hall S, Galea I, Bulters D. Risk of subarachnoid haemorrhage reduces with blood pressure values below hypertensive thresholds. Eur J Neurol 2024; 31:e16105. [PMID: 37877683 PMCID: PMC11236026 DOI: 10.1111/ene.16105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2023] [Revised: 09/20/2023] [Accepted: 10/02/2023] [Indexed: 10/26/2023]
Abstract
BACKGROUND Hypertension is a known risk factor for subarachnoid haemorrhage (SAH). The aim of this study was to describe the relationship between blood pressure and SAH using a large cohort study and perform a meta-analysis of the published literature. METHODS Participants in the UK Biobank were followed up via electronic records until 31 March 2017. Cox proportional hazards models were used to analyse the association between baseline blood pressure (systolic blood pressure [SBP], diastolic blood pressure [DBP] and MABP [mean arterial blood pressure]) and subsequent aneurysmal SAH. Linearity was assessed by comparing models including and excluding cubic splines. Electronic databases were searched from inception until 11 February 2022 for studies reporting on blood pressure and SAH. RESULTS A total of 500,598 individuals were included with 539 (0.001%) suffering from aneurysmal SAH. Nonlinear models including cubic splines visually appeared linear between SBP of 110 and 180 mmHg and there was minimal difference in fit between linear and nonlinear models. When values were stratified, those with SBP 120-130 mmHg were at higher risk compared to those with SBP <120 mmHg (hazard ratio [HR] 1.41 [1.02, 1.95]). The meta-analysis demonstrated a similar increased risk of SAH in individuals with SBP 120-130 mmHg relative to those with <120 mmHg (HR 1.41 [1.17, 1.72]). A stepwise increase in risk was also seen at each subsequent threshold (130-140 mmHg: HR 1.85 [1.53, 2.24], 140-160 mmHg: HR 2.16 [1.57, 2.98], 160-180 mmHg: HR 2.81 [1.85, 4.29], >180 mmHg: HR 5.84 [1.94, 17.54]). CONCLUSIONS The rate of SAH increases linearly with higher SBP in the general population and specifically appears lower in those with SBP <120 mmHg.
Collapse
Affiliation(s)
- Frederick Ewbank
- Department of NeurosurgeryUniversity Hospital Southampton NHS Foundation TrustSouthamptonUK
| | - Benjamin Gaastra
- Department of NeurosurgeryUniversity Hospital Southampton NHS Foundation TrustSouthamptonUK
- Faculty of MedicineUniversity of SouthamptonSouthamptonUK
| | - Samuel Hall
- Department of NeurosurgeryUniversity Hospital Southampton NHS Foundation TrustSouthamptonUK
| | - Ian Galea
- Faculty of MedicineUniversity of SouthamptonSouthamptonUK
| | - Diederik Bulters
- Department of NeurosurgeryUniversity Hospital Southampton NHS Foundation TrustSouthamptonUK
- Faculty of MedicineUniversity of SouthamptonSouthamptonUK
| |
Collapse
|
2
|
Javed K, Ahmad S, Qin J, Mowrey W, Kadaba D, Liriano G, Fortunel A, Holland R, Khatri D, Haranhalli N, Altschul D. Higher Incidence of Unruptured Intracranial Aneurysms among Black and Hispanic Women on Screening MRA in Large Urban Populations. AJNR Am J Neuroradiol 2023; 44:574-579. [PMID: 37105681 PMCID: PMC10171375 DOI: 10.3174/ajnr.a7856] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2022] [Accepted: 03/27/2023] [Indexed: 04/29/2023]
Abstract
BACKGROUND AND PURPOSE Intracranial aneurysms have a reported prevalence of 1%-2% in the general population. Currently, only patients with a strong family history or autosomal dominant polycystic kidney disease are screened for intracranial aneurysms using MRA. The purpose of this study was to determine whether there are other specific patient populations at risk that should be offered screening for intracranial aneurysms. MATERIALS AND METHODS This is a retrospective case-control study of adult patients who underwent a screening MRA of their brain at our comprehensive stroke center from 2011 to 2020. Patients with a history of a known brain aneurysm were excluded. Data were extracted on patient demographics and medical comorbidities. Bivariate analyses were performed, followed by multivariable logistic regression, to identify factors associated with a positive MRA screen for incidental aneurysms. RESULTS Of 24,397 patients eligible for this study, 2084 screened positive for a possible intracranial aneurysm. On bivariate analysis, significant differences were present in the following categories: age, sex, race and ethnicity, chronic constipation, and hyperlipidemia. On logistic regression analysis, older age (+10 years: OR = 10.01; 95% CI, 10.01-10.02; P = .001), female sex (OR = 1.37; 95% CI, 1.24-1.51; P = .001), non-Hispanic Black (OR = 1.19; 95% CI, 1.02-1.40; P = .031), and Hispanic ethnicity (OR = 1.35; 95% CI, 1.16-1.58; P = .001) versus non-Hispanic White remained significant when adjusted for other factors. CONCLUSIONS Targeted screening for high-risk elderly women of Black or Hispanic descent will yield higher positive findings for brain aneurysms, which may mitigate the risk of rupture. Whether this is a cost-effective approach has yet to be determined.
Collapse
Affiliation(s)
- K Javed
- From the Departments of Neurological Surgery (K.J., S.A., D.K., G.L., A.F., R.H., D.K., N.H., D.A.)
| | - S Ahmad
- From the Departments of Neurological Surgery (K.J., S.A., D.K., G.L., A.F., R.H., D.K., N.H., D.A.)
| | - J Qin
- Epidemiology & Population Health (J.Q., W.M.), Montefiore Medical Center, Bronx, New York
| | - W Mowrey
- Epidemiology & Population Health (J.Q., W.M.), Montefiore Medical Center, Bronx, New York
| | - D Kadaba
- From the Departments of Neurological Surgery (K.J., S.A., D.K., G.L., A.F., R.H., D.K., N.H., D.A.)
| | - G Liriano
- From the Departments of Neurological Surgery (K.J., S.A., D.K., G.L., A.F., R.H., D.K., N.H., D.A.)
| | - A Fortunel
- From the Departments of Neurological Surgery (K.J., S.A., D.K., G.L., A.F., R.H., D.K., N.H., D.A.)
| | - R Holland
- From the Departments of Neurological Surgery (K.J., S.A., D.K., G.L., A.F., R.H., D.K., N.H., D.A.)
| | - D Khatri
- From the Departments of Neurological Surgery (K.J., S.A., D.K., G.L., A.F., R.H., D.K., N.H., D.A.)
| | - N Haranhalli
- From the Departments of Neurological Surgery (K.J., S.A., D.K., G.L., A.F., R.H., D.K., N.H., D.A.)
| | - D Altschul
- From the Departments of Neurological Surgery (K.J., S.A., D.K., G.L., A.F., R.H., D.K., N.H., D.A.)
| |
Collapse
|
3
|
Haemmerli J, Morel S, Georges M, Haidar F, Chebib FT, Morita A, Nozaki K, Tominaga T, Bervitskiy AV, Rzaev J, Schaller K, Bijlenga P. Characteristics and Distribution of Intracranial Aneurysms in Patients with Autosomal Dominant Polycystic Kidney Disease Compared with the General Population: A Meta-Analysis. KIDNEY360 2023; 4:e466-e475. [PMID: 36961086 PMCID: PMC10278849 DOI: 10.34067/kid.0000000000000092] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/22/2022] [Accepted: 01/30/2023] [Indexed: 03/25/2023]
Abstract
Key Points IAs location distribution in patients with ADPKD differ from the ones in non-ADPKD patients IAs in patients with ADPKD are more commonly located in the anterior circulation and in large caliber arteries Because of IA multiplicity and singular IA distribution, patients with ADPKD represent a special population who need to be closely followed Background Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic condition associated with intracranial aneurysms (IAs). The associated pathophysiology remains unknown, but an association with wall shear stress is suspected. Cerebral arterial location is the principal factor influencing IA natural history. This study aims to compare IA location-specific distribution between ADPKD and non-ADPKD patients. Methods The ADPKD group comprised data from a systematic review of the literature (2016–2020, N =7) and three cohorts: integrated biomedical informatics for the management of cerebral aneurysms, Novosibirsk, and Unruptured Cerebral Aneurysms Study. The non-ADPKD group was formed from the integrated biomedical informatics for the management of cerebral aneurysms, Unruptured Cerebral Aneurysms Study, International Stroke Genetics Consortium, and the Finnish cohort from the literature. Patients and IAs characteristics were compared between ADPKD and non-ADPKD groups, and a meta-analysis for IA locations was performed. Results A total of 1184 IAs from patients with ADPKD were compared with 21,040 IAs from non-ADPKD patients. In total, 78.6% of patients with ADPKD had hypertension versus 39.2% of non-ADPKD patients. A total of 32.4% of patients with ADPKD were smokers versus 31.5% of non-ADPKD patients. In total, 30.1% of patients with ADPKD had a positive family history for IA versus 15.8% of the non-ADPKD patients. Patients with ADPKD showed a higher rate of IA multiplicity (33.2% versus 23.1%). IAs from patients with ADPKD showed a significant predominance across the internal carotid and middle cerebral arteries. Posterior communicating IAs were more frequently found in the non-ADPKD group. The meta-analysis confirmed a predominance of IAs in the patients with ADPKD across large caliber arteries (odds ratio [95% confidence interval]: internal carotid artery: 1.90 [1.10 to 3.29]; middle cerebral artery: 1.18 [1.02–1.36]). Small diameter arteries, such as the posterior communicating, were observed more in non-ADPKD patients (0.21 [0.11–0.88]). Conclusion This analysis shows that IAs diagnosed in patients with ADPKD are more often localized in large caliber arteries from the anterior circulation in comparison with IAs in non-ADPKD patients. It shows that primary cilia driven wall shear stress vessel remodeling to be more critical in cerebral anterior circulation large caliber arteries.
Collapse
Affiliation(s)
- Julien Haemmerli
- Division of Neurosurgery, Department of Clinical Neurosciences, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland
| | - Sandrine Morel
- Division of Neurosurgery, Department of Clinical Neurosciences, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland
- Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland
| | - Marc Georges
- Division of Neurosurgery, Department of Clinical Neurosciences, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland
| | - Fadi Haidar
- Division of Nephrology, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
- Division of Transplantation, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
| | - Fouad T. Chebib
- Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota
| | - Akio Morita
- Department of Neurological Surgery, Nippon Medical School, Tokyo, Japan
| | - Kazuhiko Nozaki
- Department of Neurosurgery, Shiga University of Medical Science, Otsu, Japan
| | - Teiji Tominaga
- Department of Neurosurgery, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - Anatoliy V. Bervitskiy
- The “Federal Centre of Neurosurgery” of the Ministry of Health of the Russian Federation Novosibirsk, Novosibirsk Region, Novosibirsk, Russia
| | - Jamil Rzaev
- The “Federal Centre of Neurosurgery” of the Ministry of Health of the Russian Federation Novosibirsk, Novosibirsk Region, Novosibirsk, Russia
| | - Karl Schaller
- Division of Neurosurgery, Department of Clinical Neurosciences, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland
| | - Philippe Bijlenga
- Division of Neurosurgery, Department of Clinical Neurosciences, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland
| |
Collapse
|
4
|
Bakker MK, Kanning JP, Abraham G, Martinsen AE, Winsvold BS, Zwart JA, Bourcier R, Sawada T, Koido M, Kamatani Y, Morel S, Amouyel P, Debette S, Bijlenga P, Berrandou T, Ganesh SK, Bouatia-Naji N, Jones G, Bown M, Rinkel GJ, Veldink JH, Ruigrok YM. Genetic Risk Score for Intracranial Aneurysms: Prediction of Subarachnoid Hemorrhage and Role in Clinical Heterogeneity. Stroke 2023; 54:810-818. [PMID: 36655558 PMCID: PMC9951795 DOI: 10.1161/strokeaha.122.040715] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2022] [Revised: 11/17/2020] [Accepted: 11/28/2022] [Indexed: 01/20/2023]
Abstract
BACKGROUND Recently, common genetic risk factors for intracranial aneurysm (IA) and aneurysmal subarachnoid hemorrhage (ASAH) were found to explain a large amount of disease heritability and therefore have potential to be used for genetic risk prediction. We constructed a genetic risk score to (1) predict ASAH incidence and IA presence (combined set of unruptured IA and ASAH) and (2) assess its association with patient characteristics. METHODS A genetic risk score incorporating genetic association data for IA and 17 traits related to IA (so-called metaGRS) was created using 1161 IA cases and 407 392 controls from the UK Biobank population study. The metaGRS was validated in combination with risk factors blood pressure, sex, and smoking in 828 IA cases and 68 568 controls from the Nordic HUNT population study. Furthermore, we assessed association between the metaGRS and patient characteristics in a cohort of 5560 IA patients. RESULTS Per SD increase of metaGRS, the hazard ratio for ASAH incidence was 1.34 (95% CI, 1.20-1.51) and the odds ratio for IA presence 1.09 (95% CI, 1.01-1.18). Upon including the metaGRS on top of clinical risk factors, the concordance index to predict ASAH hazard increased from 0.63 (95% CI, 0.59-0.67) to 0.65 (95% CI, 0.62-0.69), while prediction of IA presence did not improve. The metaGRS was statistically significantly associated with age at ASAH (β=-4.82×10-3 per year [95% CI, -6.49×10-3 to -3.14×10-3]; P=1.82×10-8), and location of IA at the internal carotid artery (odds ratio=0.92 [95% CI, 0.86-0.98]; P=0.0041). CONCLUSIONS The metaGRS was predictive of ASAH incidence, although with limited added value over clinical risk factors. The metaGRS was not predictive of IA presence. Therefore, we do not recommend using this metaGRS in daily clinical care. Genetic risk does partly explain the clinical heterogeneity of IA warranting prioritization of clinical heterogeneity in future genetic prediction studies of IA and ASAH.
Collapse
Affiliation(s)
- Mark K. Bakker
- Department of Neurology and Neurosurgery, University Medical Center Utrecht Brain Center, Utrecht University, the Netherlands (M.K.B., J.P.K., G.J.E.R., Y.M.R., J.H.V.)
| | - Jos P. Kanning
- Department of Neurology and Neurosurgery, University Medical Center Utrecht Brain Center, Utrecht University, the Netherlands (M.K.B., J.P.K., G.J.E.R., Y.M.R., J.H.V.)
| | - Gad Abraham
- Cambridge Baker Systems Genomics Initiative, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia (G.A.)
- Department of Clinical Pathology, University of Melbourne, Parkville, VIC, Australia (G.A.)
| | - Amy E. Martinsen
- Department of Research and Innovation, Division of Clinical Neuroscience, Oslo University Hospital, Norway (A.E.M., B.S.W., J.-A.Z.)
- Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Norway (A.E.M., J.-A.Z.)
- K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Trondheim, Norway (A.E.M., B.S.W., J.-A.Z.)
| | - Bendik S. Winsvold
- K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Trondheim, Norway (A.E.M., B.S.W., J.-A.Z.)
- Department of Neurology, Oslo University Hospital, Norway (B.S.W.)
| | - John-Anker Zwart
- Department of Research and Innovation, Division of Clinical Neuroscience, Oslo University Hospital, Norway (A.E.M., B.S.W., J.-A.Z.)
- Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Norway (A.E.M., J.-A.Z.)
- K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Trondheim, Norway (A.E.M., B.S.W., J.-A.Z.)
| | - Romain Bourcier
- Université de Nantes, CHU Nantes, INSERM, CNRS, l’institut du thorax, France (R.B.)
- CHU Nantes, Department of Neuroradiology, France (R.B.)
| | - Tomonobu Sawada
- Graduate School of Frontier Sciences, The University of Tokyo, Japan (T.S., Y.K.)
| | - Masaru Koido
- Laboratory for Statistical and Translational Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan (M.K.)
- Department of Cancer Biology, Institute of Medical Science, The University of Tokyo, Japan (M.K.)
| | - Yoichiro Kamatani
- Graduate School of Frontier Sciences, The University of Tokyo, Japan (T.S., Y.K.)
| | - Sandrine Morel
- Neurosurgery Division, Department of Clinical Neurosciences, Faculty of Medicine, Geneva University Hospitals, Switzerland (P.B., S.M.)
- Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Switzerland (S.M.)
| | - Philippe Amouyel
- LabEx DISTALZ-U1167, RID-AGE-Risk Factors and Molecular Determinants of Aging-Related Diseases, University of Lille, Lille, France; Inserm U1167, Lille, France; Centre Hospitalier Universitaire Lille, Lille, France; Institut Pasteur de Lille, Lille, France (P.A.)
| | - Stéphanie Debette
- University of Bordeaux, INSERM, Bordeaux Population Health Center, UMR1219, Bordeaux, France (S.D.)
- Bordeaux University Hospital, Department of Neurology, Institute of Neurodegenerative Diseases, France (S.D.)
| | - Philippe Bijlenga
- Neurosurgery Division, Department of Clinical Neurosciences, Faculty of Medicine, Geneva University Hospitals, Switzerland (P.B., S.M.)
| | | | - Santhi K. Ganesh
- Division of Cardiovascular Medicine, Department of Internal Medicine (S.K.G.), University of Michigan Medical School, Ann Arbor
- Department of Human Genetics (S.K.G.), University of Michigan Medical School, Ann Arbor
| | | | - Gregory Jones
- Department of Surgery, University of Otago, Dunedin, New Zealand (G.J.)
| | - Matthew Bown
- Department of Cardiovascular Sciences and National Institute for Health Research (M.B.)
- Leicester Biomedical Research Centre (M.B.)
- University of Leicester, Glenfield Hospital, United Kingdom (M.B.)
| | - Gabriel J.E. Rinkel
- Department of Neurology and Neurosurgery, University Medical Center Utrecht Brain Center, Utrecht University, the Netherlands (M.K.B., J.P.K., G.J.E.R., Y.M.R., J.H.V.)
| | - Jan H. Veldink
- Department of Neurology and Neurosurgery, University Medical Center Utrecht Brain Center, Utrecht University, the Netherlands (M.K.B., J.P.K., G.J.E.R., Y.M.R., J.H.V.)
| | - Ynte M. Ruigrok
- Department of Neurology and Neurosurgery, University Medical Center Utrecht Brain Center, Utrecht University, the Netherlands (M.K.B., J.P.K., G.J.E.R., Y.M.R., J.H.V.)
| |
Collapse
|